SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
TASOX can be safely and efficaciously delivered after short course radiation, resulting in
significant pathologic downstaging, allowing for an R0 pelvic resection, and providing local
control in appropriately selected stage II/III rectal cancer patients treated with
contemporary TME-based surgery.